2μg (R: reducing condition, N: non-reducing condition).
RANTES/CCL5 Protein, Human
RANTES/CCL5 Protein, Human
Price:
Regular price
$189.00 USD
Regular price
Sale price
$189.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | CCL-5, D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228, eoCP, C-C motif chemokine ligand 5 |
| Accession | P13501 |
| Amino Acid Sequence | Ser24-Ser91 |
| Expression System | E.coli |
| Molecular Weight | 8kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | 50mM Gly, 500mM NaCl, pH10.0 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1.Xu J, Shi Q, Lou J, Wang B, Wang W, Niu J, Guo L, Chen C, Yu Y, Huang Y, Guo W,Lan J, Zhu Y, Ren T, Tang X. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. J Immunother Cancer. 2023 Apr;11(4):e006808. |
Background
Chemokines form a superfamily of secreted
proteins involved in immunoregulatory and inflammatory processes. CC motif
chemokine ligand 5 (CCL5), a member of the CC subfamily, functions as a
chemoattractant for blood monocytes, memory T helper cells and eosinophils. It
functions as one of the natural ligands for the chemokine receptor chemokine
(C-C motif) receptor 5 (CCR5), and it suppresses in vitro replication of the R5
strains of HIV-1, which use CCR5 as a coreceptor.Researches
demonstrate that chordoma accelerated tumor progression through autocrine CCL5
acting on tumor cells and paracrine CCL5 polarizing macrophages into M2 TAMs to
facilitate immune escape. Targeting M2 macrophages and the CCL5–CCR5 axis is
therefore expected to improve the prognosis of patients with chordoma.
Picture
Picture
SDS-PAGE
